VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study

NEXT STORY
Pluristem Provides Update on COVID-19:  Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity
PREV STORY
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ThromboGenics Business Update – Q3 2017

Press release                                                          20 October, 2017Regulated Information Diabetic Eye Disease programs progressing €53.7 million cash ...

author_avatar
NASDAQ Market News

Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

author_avatar
NASDAQ Market News

Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA

author_avatar
NASDAQ Market News